Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
Paz-Ares L, Borghaei H, Liu S, Peters S, Herbst R, Stencel K, Majem M, Czyżewicz G, Bernabe Caro R, Lee K, Johnson M, Karadurmus N, Grohe C, Cuchelkar V, Graupner V, Kaul M, Lin Y, Chakrabarti D, Bhatt K, Reck M. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Journal Of Clinical Oncology 2025, 43: 8006-8006. DOI: 10.1200/jco.2025.43.16_suppl.8006.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerReceipt of prophylactic cranial irradiationGlobal phase 3 studySmall cell lung cancerProphylactic cranial irradiationPlatinum-based chemotherapySignificant OS benefitPhase 3 studyCell lung cancerClinically meaningful benefitLong-term survivalMaintenance phaseStratified log-rankPD-(L)1RECIST v1.1ECOG PSOS benefitOS improvementCranial irradiationLiver metastasesOpen-labelEligible ptsAggressive diseaseFirst-linePrimary endpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply